Monday 1 July 2024

The Pharma Letter Podcast — Episode 11 — Should US states control drug prices?

Biotechnology
Simon Wentworth
4 March 2022
episode11-big

More on this story...

Pharmaceutical
The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?
10 February 2022
Biotechnology
The Pharma Letter Podcast — Episode 9 — The rise of AI in drug discovery
30 December 2021
Biotechnology
The Pharma Letter Podcast — Episode 8 — Why hasn't the world embraced Sputnik V?
14 December 2021
Pharmaceutical
Will the unintended consequences of drug price transparency regulation outweigh its benefits?
18 March 2022


More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze